Price Vision Group
11
2
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
27.3%
3 terminated/withdrawn out of 11 trials
66.7%
-19.8% vs industry average
9%
1 trials in Phase 3/4
133%
8 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Corneal Crosslinking for Treatment of Corneal Neovascularization
Role: lead
Comparison of Standard vs. Accelerated Corneal Crosslinking
Role: lead
Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Role: lead
Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration
Role: lead
Effect of Xen Implantation on the Aqueous Humor Proteome
Role: lead
Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
Role: lead
Effect of TrueTear Corneal Surface Imaging
Role: lead
Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Role: lead
Cross Linking for Treatment of Corneal Infection
Role: lead
Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty
Role: collaborator
Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)
Role: lead
All 11 trials loaded